Twenty-year changes of penta-chlorodibenzofuran (PeCDF) level and symptoms in Yusho patients, using association analysis

Shinya Matsumoto*1, Yoshiyuki Kanagawa1, Soichi Koike1, Manabu Akahane2, Hiroshi Uchi3, Satoko Shibata3, Masutaka Furue3 and Tomoaki Imamura2

Abstract

Background: Recently, methods for measurement of dioxins in the blood have improved. Also, techniques for analyzing large quantities of data have been developed, such as data mining. Even in subjects with elusive characteristics, it is becoming possible to find previously unknown characteristics by checking all combinations of symptoms.

Findings: Using association analysis of the data mining technique, we extracted and compared combinations with a strong relationship between recent symptoms (2001-2004) and recent blood PeCDF levels, and between past symptoms (1986-1989) and recent PeCDF levels, in physical, blood, dermatological, dental and ophthalmological examinations.

Patients with a higher PeCDF level were more likely to present with symptoms included in the diagnostic criteria, such as pigmentation. In addition, we obtained evidence that recent PeCDF levels had a stronger relationship with recent than past symptoms.

Conclusions: Recent PeCDF levels should not be compared directly with past symptoms. However, as the excretion rate of PeCDF has been constant, it is probable that PeCDF levels were higher in the past if recent PeCDF levels were also high. The study confirmed a relationship between past PeCDF levels and past clinical symptoms. For symptoms included in the diagnostic criteria, there was a stronger relationship between PeCDF levels and past symptoms than recent symptoms. Alleviation of symptoms in each patient or aging weakened the relationship between PeCDF levels and symptoms.

Background

Kanemi Yusho is a form of food poisoning that was caused by rice bran oil in 1968 in Western Japan, especially in Northern Kyushu [1]. Initially, polychlorinated biphenyls (PCBs), which are used as a heat medium in the process of rice bran oil manufacture, were considered as the causative agents. However, subsequent research threw suspicion on 2,3,4,7,8-penta-chlorodibenzofurans (PeCDFs), which are dioxins that result from heat-denatured PCB, as causative agents. Today, PCBs and their derivatives are considered to be the main causative agents of Kanemi Yusho [1-5].

With recent advances in measurement techniques for dioxins such as PeCDF, measurement of blood PeCDF levels has become possible using the same amount of blood as that used in the annual examinations. Since the Yusho examinations in 2001, PeCDF measurement has started for patients who wish such an examination [6,7].

A few decades have passed since the occurrence of Kanemi Yusho, and the symptoms at the initial phase have already disappeared. We have reported previously the relationship between clinical symptoms of Yusho patients and dioxins, one of the causative agents of Yusho [8,9]. Until now, collective results that show the relationship between Yusho and its symptoms have been...
reported [10]. In addition, several reports have compared these results [2]. Direct comparison of the latest and previous reports is difficult because study patients may have differed between the studies. In addition, it is difficult to differentiate between patients' low exposure to PeCDF, when the incident occurred, and amelioration of symptoms over time.

Recently, methods for mass data analysis, e.g. data mining, have improved markedly. In particular, it has become possible to scrutinize and evaluate many combinations of symptoms which had been considered too large to handle previously [11]. This study used data mining to investigate the relationship between recent/past symptoms and PeCDF levels in the same patients, and the relationship between PeCDF levels and symptoms at a time close to the occurrence of Kanemi Yusho. It is currently difficult to distinguish the characteristic Yusho symptoms from aging symptoms. As a result of the long half-life of PeCDF, patients who ingested a large amount of PeCDF at the time of the accident still have high levels of PeCDF, albeit with a gradual reduction over time.

We think that the association between the symptoms and PeCDF level can be examined more properly by using data from the period when the characteristic Yusho symptoms were still evident. As a result of the long half-life of PeCDF, patients who ingested a large amount of PeCDF at the time of the accident still have high levels of PeCDF, albeit with a gradual reduction over time.

We used association analysis [12] to identify symptoms that were strongly related to PeCDF level. Association analysis was applied in medical domain [8,13]. The numerical value that indicated the level of association with PeCDF level was compared between the strongly associated past and recent symptoms. The proportion of patients with high PeCDF levels and those with each symptom were calculated. If a high level of PeCDF and the presence of each symptom were not related, the rate of patients with a certain symptom among those with high PeCDF levels was calculated as the product of both proportions, and is binomially distributed. If the sample size was adequate, the binomial distribution could be considered as a normal distribution. The relation of symptom to the PeCDF level was judged based on how the symptom was distributed in the probability distribu-

### Methods

#### Subjects and examination items

After the occurrence of Kanemi Yusho, health examinations for designated Yusho patients (hereinafter referred to as Yusho examinations) have been conducted since 1986. We used data on the presence or absence of symptoms in physical, blood, dermatological, dental and ophthalmological examinations in Yusho patients who had undergone annual examinations in 1986-1989 and 2001-2004, at least once in each period, and whose PeCDF levels were measured. Subjects included both designated and undesignated patients. The number of subjects who underwent examinations in both periods was 302. To analyze the relationship with recent PeCDF levels, representative values were obtained for each item in the physical, blood, dermatological, dental and ophthalmological examinations for each year in 1986-1989 and 2001-2004, for each patient. We defined abnormality as one or more abnormal values in 4 years. Yusho examinations consisted of a total of 241 items, including 52 items in a questionnaire, 55 in physical and laboratory examinations, 21 in dermatological examinations, 108 in dental examinations, and five in ophthalmological examinations [1,7].

#### Methods for data analysis

We found laboratory parameters that were related strongly to recent PeCDF level among the past and recent data. We used association analysis [12] to identify symptoms that were strongly related to PeCDF level. Association analysis was applied in medical domain [8,13]. The numerical value that indicated the level of association with PeCDF level was compared between the strongly associated past and recent symptoms. The proportion of patients with high PeCDF levels and those with each symptom were calculated. If a high level of PeCDF and the presence of each symptom were not related, the rate of patients with a certain symptom among those with high PeCDF levels was calculated as the product of both proportions, and is binomially distributed. If the sample size was adequate, the binomial distribution could be considered as a normal distribution. The relation of symptom to the PeCDF level was judged based on how the symptom was distributed in the probability distribu-

### Table 1: Recent symptoms with independently high relationship with high PeCDF level (≥ 50 pg/g lipid)

| Symptoms                  | Rate of patients with symptom | Rate of patients with high PeCDF | Z score |
|---------------------------|-------------------------------|---------------------------------|---------|
| PCB pattern (A)           | 0.411                         | 0.774                           | 3.513   |
| Past pigmentation (+)     | 0.487                         | 0.667                           | 1.901   |
| Uric acid (high)          | 0.301                         | 0.692                           | 1.755   |

### Table 2: Past symptoms with independently high relationship with high PeCDF level (≥ 50 pg/g lipid)

| Symptoms                  | Rate of patients with symptom | Rate of patients with high PeCDF | Z score |
|---------------------------|-------------------------------|---------------------------------|---------|
| PCB pattern (A)           | 0.427                         | 0.791                           | 3.891   |
| Uric acid (high)          | 0.205                         | 0.758                           | 2.135   |
| PCB pattern (B)           | 0.272                         | 0.707                           | 1.846   |
tion. Z-score was used to show the difference from the mean in the normal distribution [8]. Association analysis revealed highly-related combinations of symptoms and PeCDF levels, which were defined as a z score ≥ 1.645 (one-tailed significance level, 5%).

Classification of examination results

Designation of Yusho was based upon the diagnostic criteria in Additional File 1[1]. The diagnostic criteria largely consist of "onset conditions," "important findings" and "reference symptoms and findings." Among these, severity of "acneform eruptions" and "pigmentation" ('important findings') was determined differently by the doctors who conducted the examinations, whereas measurement of "abnormalities of blood PCB properties and levels," "abnormalities of blood polychlorinated quarterphenyl (PCQ) properties and levels" and "abnormalities of blood PeCDF levels" can be expressed numerically, thereby playing an important role in determining designation.

To conduct association analysis, the numerical data were classified into categorical data such as "within the normal range" and "abnormal values". For general blood examination, standard values that the study group used in examinations were used to define "normal range". Findings from the physical, dermatological, dental and ophthalmological examinations were each classified by the presence or absence of abnormalities, and their strength.

With regard to PCBs, it is known that chromatographic analysis patterns in Yusho patients differ from those in the general population. Patterns are classified into four types: Type A, which is specific to Yusho patients; Type C, which is specific to the general population; Type B, which is intermediate between Types A and C; and Type BC, which is intermediate between Types B and C.

For PCQ levels, it was considered that ≥ 0.1 ppb was abnormally high; ≤ 0.02 ppb (detection limit) was normal; and 0.03-0.09 ppb was borderline. As for PeCDF level, "50 pg/g lipid or above" and < 50 pg/g lipid were classified as high and normal level, respectively.

Results

Table 1 indicates the recent symptoms that were independently highly related to recent high PeCDF level (≥ 50 pg/g lipid): Type A PCB pattern, past pigmentation, and high uric acid level.

Table 2 indicates the past symptoms that were highly related to recent high PeCDF level (≥ 50 pg/g lipid): Type A and B PCB pattern, and high uric acid level.

Table 3 compares the z score between recent and past symptoms that were highly related to recent high PeCDF level (≥ 50 pg/g lipid). Recent symptoms had a lower z score than past symptoms for Type A PCB pattern and high uric acid level. Type B PCB pattern was more strongly related to past than recent symptoms.

Table 4: Recent symptoms with independently low relationship with low PeCDF level (< 50 pg/g lipid)

| Symptoms                           | Rate of patients with symptom | Rate of patients with high PeCDF | Z score |
|-----------------------------------|-------------------------------|---------------------------------|---------|
| PCB pattern (C)                   | 0.185                         | 0.893                           | 5.439   |
| Odontogenesis imperfecta (+)      | 0.017                         | 1.000                           | 1.930   |
| Hepatomegaly (+)                  | 0.073                         | 0.682                           | 1.795   |
| Urinary protein (abnormal)        | 0.142                         | 0.605                           | 1.756   |
| Nutrition (thin)                  | 0.023                         | 0.857                           | 1.710   |
| Inorganic phosphorus (low)        | 0.040                         | 0.750                           | 1.677   |
| Palpebral conjunctiva pigmentation (+ or above) | 0.070                         | 0.667                           | 1.646   |

≤ 1.645 indicates lack of significant association.
Table 4 indicates the recent symptoms that were independently highly related to recent low PeCDF level (< 50 pg/g lipid). Type C PCB pattern showed the strongest relationship, and there was also a strong relationship with odontogenesis imperfecta.

Table 5 indicates past symptoms that were independently highly related to recent low PeCDF level (< 50 pg/g lipid). Type C PCB pattern showed the strongest relationship, and high albumin level also appeared as a symptom.

Table 6 compares the z score between recent and past symptoms that were highly related to recent low PeCDF level (< 50 pg/g lipid). Recent symptoms had a lower z score than past symptoms for Type C PCB pattern, therefore, it was more strongly related to past than recent symptoms. In addition, odontogenesis imperfecta and hepatomegaly appeared only as past symptoms.

Figure 1 shows the prevalence of a high level of uric acid. This was more strongly associated with PeCDF ≥ 50 pg/g lipid than < 50 pg/g lipid. The odds ratio of prevalence between the PeCDF ≥ 50 pg/g lipid and < 50 pg/g lipid groups was 2.93 in the past. The odds ratio was 2.15 in the recent period.

**Discussion**

Type A PCB pattern was strongly related to high PeCDF level (≥ 50 pg/g lipid), and Type C pattern was strongly related to low PeCDF level (< 50 pg/g lipid). In addition, the results showed that Type B PCB pattern was related to high PeCDF level in the past, but there was no such tendency more recently. Specifically, the results suggested a stronger relationship with the past than with the recent PCB pattern. In the past, measuring trace dioxins was difficult. Gas chromatography was used to measure mass per molecular weight as a relative amount. PCB patterns were determined based on peaks, i.e., molecular weights at which relative amounts increase. PCB pattern Type A is known to be specific to Yusho, Type C is found in the general population, and Type B is intermediate between

### Table 4: Past symptoms with independently low relationship with low PeCDF level (< 50 pg/g lipid)

| Symptoms                                      | Rate of patients with symptom | Rate of patients with high PeCDF | Z score |
|-----------------------------------------------|-------------------------------|---------------------------------|---------|
| PCB pattern (C)                               | 0.182                         | 0.855                           | 4.937   |
| Smoking state (+)                             | 0.169                         | 0.667                           | 2.623   |
| Albumin (high)                                | 0.046                         | 0.786                           | 2.019   |
| Inferior gingival pigmentation (brown)        | 0.162                         | 0.612                           | 1.968   |
| Blood glucose (low)                           | 0.033                         | 0.800                           | 1.771   |
| Total bilirubin (high)                        | 0.119                         | 0.611                           | 1.659   |

Table 5: Past symptoms with independently low relationship with low PeCDF level (< 50 pg/g lipid)

| Symptoms                                      | Rate of patients with symptom | Rate of patients with high PeCDF | Z score |
|-----------------------------------------------|-------------------------------|---------------------------------|---------|
| PCB pattern (C)                               | 0.182                         | 0.855                           | 4.937   |
| Smoking state (+)                             | 0.169                         | 0.667                           | 2.623   |
| Albumin (high)                                | 0.046                         | 0.786                           | 2.019   |
| Inferior gingival pigmentation (brown)        | 0.162                         | 0.612                           | 1.968   |
| Blood glucose (low)                           | 0.033                         | 0.800                           | 1.771   |
| Total bilirubin (high)                        | 0.119                         | 0.611                           | 1.659   |

Table 6: Comparison of z score of symptoms with low relationship with low PeCDF level (< 50 pg/g lipid)

| Symptoms                                      | Past             | Recent        |
|-----------------------------------------------|-----------------|---------------|
| PCB pattern (C)                               | 5.439           | 4.937         |
| Odontogenesis imperfecta (+)                  | 1.930           | ≤ 1.645       |
| Hepatomegaly (+)                              | 1.795           | ≤ 1.645       |
| Urinary protein (abnormal)                    | 1.756           | ≤ 1.645       |
| Nutrition (thin)                              | 1.710           | ≤ 1.645       |
| Inorganic phosphorus (low)                    | 1.677           | ≤ 1.645       |
| Palpebral conjunctiva pigmentation (+ or above)| 1.646           | ≤ 1.645       |
| Smoking state (+)                             | ≤ 1.645         | 2.623         |
| Albumin (high)                                | ≤ 1.645         | 2.019         |
| Inferior gingival pigmentation (brown)        | ≤ 1.645         | 1.968         |
| Blood glucose (low)                           | ≤ 1.645         | 1.771         |
| Total bilirubin (high)                        | ≤ 1.645         | 1.659         |

≤ 1.645 indicates lack of significant association.
because the excretion rate of PeCDF has been constant times. However, we consider that comparison is valid because the excretion rate of PeCDF has been constant over time [1], and this was a cohort study that allowed identification of each patient in the annual examinations.

Limitations
There was no direct relationship between past symptoms and recent measurements because of problems with the excretion rate of PeCDF, therefore, the levels should be considered as reference values. In addition, patients might have been exposed to organochlorine compounds between the periods compared; i.e. 1986-1989 and 2001-2004. However, it can be assumed that the level of such exposure would have been far lower than the level that was already present in Yusho patients. Furthermore, there might be other diseases that can develop in association with aging and other factors. It is unlikely that another disease was involved, but we will be able to clarify this by further investigating the symptoms observed in this study.

Conclusion
In this analysis, we studied the relationship between recent PeCDF levels and recent/past symptoms. The past symptoms in patients with high PeCDF levels were similar to the symptoms described in the diagnostic criteria of Yusho. Patients with recent high PeCDF levels also had past high PeCDF, and a relationship with past symptoms is therefore assumed. Past symptoms were demonstrated to have a stronger relationship with PeCDF level than were recent symptoms. Alleviation of symptoms in each patient, or an increase in symptoms because of aging, was shown to decrease the clarity of symptoms.

Additional material

Additional file 1 Appendix 1: Diagnostic criteria for Yusho (as presently supplemented).

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
SM designed the study, drafted the manuscript, designed the data analysis, and analyzed the data. YK, SK and MA assisted with drafting the manuscript. HU, SS and MF collected the data. TI designed the whole study and assisted with manuscript drafting. All the authors reviewed the final manuscript and gave their approval.

Acknowledgements
We acknowledge the support from a Grant-in-Aid for scientific research from the Ministry of Health, Labour and Welfare, Japan.

Author Details
1 Department of Planning Information and Management, The University of Tokyo Hospital, Tokyo, Japan, 2Department of Public Health, Health Management and Policy, Nara Medical University School of Medicine, Kashihara, Japan and 3Department of Dermatology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan

Received: 12 January 2010 Accepted: 5 May 2010
Published: 5 May 2010
References

1. Furue M, Uenotsuchi T, Urabe K, Ishikawa T, Kuwabara M: Overview of Yusho. J Dermatol Sci 2005, 38:53-60.

2. Yoshimura T: Yusho in Japan. J Dermatol Sci 2003, 41:139-148.

3. Toyoda M, Utibe H, Yanagi T, Kono Y, Hori S, Iida T: Intake of PCDDs, PCDFs, and Coplanar PCBs via meals in Japan. Shokuhin Eiseigaku Zasshi 1999, 40:88-110.

4. Hamada M, Masuda Y, Hirayama C: Blood levels of polychlorinated biphenyls in patients with polychlorinated biphenyls poisoning after fasting. Igakunoayumi 1977, 101:78-79.

5. Iida T, Todaka T, Hirakawa H, Tobishi K, Matsueda T, Hori T, et al.: Follow-up survey of dioxins in the blood of Yusho (in 2001). Fukuoka Igaku Zasshi 2003, 94:16-135.

6. Todaka T, Hitakawa H, Tobishi K, Iida T: New protocol of dioxins analysis in human blood. Fukuoka Igaku Zasshi 2003, 94:148-157.

7. Kanagawa Y, Imamura T: Relationship of clinical symptoms and laboratory findings with the blood levels of PCDFs in patients with Yusho. J Dermatol Sci 2005:585-593.

8. Hamada M, Kanagawa Y, Matsumoto S, Tajima B, Uenotsuchi T, Shibata S, Furue M: Relationship between clinical features and blood levels of pentachlorodibenzofuran in patients with Yusho. Environ Toxicol 2007, 221:24-111.

9. Kanagawa Y, Matsumoto S, Koike S, Tajima B, Fukiwake N, Shibata S, Uchi H, Furue M, Imamura T: Association of clinical findings in Yusho patients with serum concentrations of polychlorinated biphenyls, polychlorinated quarterphenyls and 2,3,4,7,8-pentachlorodibenzofuran more than 30 years after the poisoning event. Environ Health 2008, 7:47.

10. Hamada M, Matsumoto S, Akahane M, Kanagawa Y, Koike S, Tajima B, Matsuya S, Uchi H, Shibata S, Furue M: Cutaneous symptoms such as acneform eruption and pigmentation are closely associated with blood levels of 2,3,4,7,8-penta-chlorodibenzofurans in Yusho patients, using data mining analysis. BMC Res Notes 2009, 2:27.

11. Hamada M, Matsumoto S, Kanagawa Y, Tajima B, Matsuya S, Furue M, Oyama H: A technique for identifying three diagnostic findings using association analysis. Med Biol Eng Comput 2007, 45:51-59.

12. Agrawal R, Imielinski T, Swami AN: Mining association rules between sets of items in large databases. ACM SIGMOD International Conference on Management of Data. Washington, DC, 1993:207-216.

13. Ordonez C, Orozco E, Braa L, Santana C, Ezquerra N: Discovering constrained association rules to predict heart disease. IEEE ICDM International Conference on Data Mining 2001.